[Oak Ridge, TN] March 2022: Cymbeline “Bem” Culiat, founder, president and chief science officer of NellOne and a former molecular geneticist at Oak Ridge National Laboratory, told Friends of ORNL recently that her company is pursuing a fast-track path toward obtaining approval of the new drug for human clinical trials through the Food and Drug Administration’s Coronavirus Treatment Acceleration Program. Read the full article published by Carolyn Krause in The Oak Ridger.
About NellOne Therapeutics, Inc.
NellOne is pioneering advances in regenerative medicine to restore injured tissue to its normal functional state. NellOne is dedicated to harnessing the power of the NELL1 / NV1 protein to improve outcomes for patients around the world, who suffer from significant soft tissue damage incurred in traumatic injuries or diseases. The NELL1 signaling protein’s healing properties are derived from its activity during early mammalian development in the production of an environment (extracellular matrix) that promotes pathways to regulate inflammation, increase cell/tissue survival under adverse conditions, recruit stem cells, and enhance blood vessel formation — thereby supporting new tissue formation and maturation to replace damaged tissues. For more information on NellOne visit nell-one.com.